“Renovation of Building 29 laboratories at the New Iberia Research Center"

– 翻新新伊比利亚研究中心的 29 栋实验室”

基本信息

项目摘要

The New Iberia Research Center (NIRC) at the University of Louisiana at Lafayette has undergone tremendous growth over the last 6 years adding some 3000 nonhuman primates for a current total of 9400 animals on site, and its research expenditure rose from ~19 to over 70 million between FY2016 and 2021. This expansion has been markedly accelerated during the COVID pandemic in 2 ways: 1) NIRC has supported the testing of no less than 12 COVID vaccines including the Pfizer-BioNTech as well as monitored the distribution and pharmacokinetics of convalescent antibodies via dynamic PET/CT imaging. 2) Owing to fact that many labs were closed across US institutions during 2020, NIRC scientists ensured that ongoing nonhuman primate experiments could be continued to avoid wasting precious resources. The expansion of NIRC’s in house HIV/AIDS research program is currently limited by the lack of additional research laboratory space to house new hires and their teams, with several candidates interested in joining NIRC and the University of Louisiana at Lafayette, which in December 2021 obtained the coveted R1 status by the Carnegie Commission on Institutions of Higher Education. In preparation of such laboratory expansion, NIRC has completed the demolition of the third floor of Building 29 (~9100 sq ft) along with complete and certified asbestos removal. This space will be ideal to house up to 6 research teams in a combination of open shared as well as separate laboratory spaces, complete with offices, cubicles and a conference room. NIRC supports many onsite and collaborative programs on using nonhuman primates on various metabolic and infectious diseases, most notably HIV lentiviral pathogenesis supported by state of the art imaging capabilities including a whole body to single cell analysis approach, therapeutic approaches aimed at curing HIV, and an extensive program to prevent mucosal viral acquisition via protective experimental vaccines, vaginal and colorectal microbicides. In addition, NIRC has been a key contributor to the fight against COVID-19. The latter pandemic has severely depleted the supply of research macaques and NIRC has been expanding its colonies via the breeding and the transfer of new programs such as the NIAID funded SVEU breeding program. In addition to over 6500 Indian origin rhesus macaques, NIRC is breeding and using Mauritian cynomolgus macaques and African green monkeys as well as a few pigtailed macaques. This NHP program is largely supported by a state-of-the-art onsite clinical laboratory, expert veterinary care and equipment. NIRC has also established an expandable rodent vivarium in the support of research and is planning to build a BSL-3 facility complete with laboratories, rodent and monkey housing. The addition of research laboratories at NIRC will markedly enhance the ability of the Center to assemble a critical mass of scientists focused on HIV research, expanding the breath of the research program fully supported by NHP models, and compete for external funding.
路易斯安那大学拉斐特大学的新伊比利亚研究中心(NIRC)经历了巨大 在过去的6年中,增长了约3000个非人类素数,目前总共有9400只动物, 它的研究支出从2016财年至2021财年之间从约19个增至7000万。 在两种方式中,在共同大流行期间明显加速了:1)NIRC支持了不少于测试 大于包括辉瑞-biontech在内的12次共同疫苗,并监视分布和 通过动态PET/CT成像的康复抗体的药代动力学。 2)由于许多实验室 NIRC科学家在2020年在美国机构中关闭,确保正在进行的非人类灵长类动物实验 可以继续避免浪费宝贵的资源。 NIRC的艾滋病毒/艾滋病研究的扩展 目前,计划受到缺乏其他研究实验室空间来容纳新员工及其的限制 团队,有几个有兴趣加入NIRC和路易斯安那大学拉斐特的候选人 2021年12月,卡内基高等教育机构委员会获得了令人垂涎的R1状态。 为了准备这种实验室扩展,NIRC完成了拆除29号建筑物的三楼 (〜9100平方英尺)以及清除棉石油的清除。这个空间最多可容纳6个 研究团队结合了开放共享以及单独的实验室空间,包括办公室, 隔间和会议室。 NIRC支持许多有关使用非人类的现场和协作计划 有关各种代谢和传染病的灵长类动物,最著名的是由 最先进的成像功能,包括全身至单细胞分析方法,治疗 旨在治愈艾滋病毒的方法,以及一项广泛的计划,以防止通过保护 实验性疫苗,阴道和结直肠菌皮。此外,NIRC一直是该公司的关键因素 与19日作战。后一种大流行严重耗尽了研究猕猴和NIRC的供应 一直通过繁殖和转移新计划(例如Niaid资助)扩大其殖民地 SVEU育种计划。除了6500多个印度恒河猕猴之外,NIRC还繁殖和使用 毛里求利亚的cynomolgus猕猴和非洲绿猴以及一些辫子的猕猴。这个NHP 计划在很大程度上得到了最先进的现场临床实验室,专家兽医护理和设备的支持。 NIRC还建立了一个可扩展的啮齿动植物,以支持研究,并计划建立一个 BSL-3设施配有实验室,啮齿动物和猴子住房。在 NIRC将明显增强中心组装批判性科学家的能力 研究,扩大NHP模型完全支持的研究计划的呼吸,并争夺 外部资金。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Francois J Villinger其他文献

Francois J Villinger的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Francois J Villinger', 18)}}的其他基金

Expansion of Macaque Breeding runs at the New Iberia Research Center
新伊比利亚研究中心扩大猕猴繁育规模
  • 批准号:
    10761902
  • 财政年份:
    2023
  • 资助金额:
    $ 200万
  • 项目类别:
Core D: Nonhuman Primates
核心 D:非人类灵长类动物
  • 批准号:
    10425029
  • 财政年份:
    2022
  • 资助金额:
    $ 200万
  • 项目类别:
Nonhuman Primate Core
非人类灵长类核心
  • 批准号:
    10460075
  • 财政年份:
    2022
  • 资助金额:
    $ 200万
  • 项目类别:
Nonhuman Primate Core
非人类灵长类核心
  • 批准号:
    10666570
  • 财政年份:
    2022
  • 资助金额:
    $ 200万
  • 项目类别:
Vaccine against HCV in nonhuman primates
非人灵长类动物 HCV 疫苗
  • 批准号:
    10797239
  • 财政年份:
    2021
  • 资助金额:
    $ 200万
  • 项目类别:
Novel Macaque Breeding Runs at the New Iberia Research Center
新伊比利亚研究中心开展新型猕猴育种工作
  • 批准号:
    10374603
  • 财政年份:
    2021
  • 资助金额:
    $ 200万
  • 项目类别:
Vaccine against HCV in nonhuman primates
非人灵长类动物 HCV 疫苗
  • 批准号:
    10409759
  • 财政年份:
    2021
  • 资助金额:
    $ 200万
  • 项目类别:
Vaccine against HCV in nonhuman primates
非人灵长类动物 HCV 疫苗
  • 批准号:
    10205548
  • 财政年份:
    2021
  • 资助金额:
    $ 200万
  • 项目类别:
Non-Human Primate and Imaging Core
非人类灵长类动物和成像核心
  • 批准号:
    10224631
  • 财政年份:
    2017
  • 资助金额:
    $ 200万
  • 项目类别:
Macque
马克
  • 批准号:
    8516869
  • 财政年份:
    2013
  • 资助金额:
    $ 200万
  • 项目类别:

相似国自然基金

非洲绿猴血管内皮细胞microRNA表达谱分析及功能研究
  • 批准号:
    31501908
  • 批准年份:
    2015
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
非洲绿猴细胞限制因子Trim5αSPRY区插入子在抗HIV-1感染中的作用
  • 批准号:
    30571661
  • 批准年份:
    2005
  • 资助金额:
    25.0 万元
  • 项目类别:
    面上项目

相似海外基金

SCIENTIFIC AND PROGRAM SUPPORT SERVICES
科学和计划支持服务
  • 批准号:
    10942909
  • 财政年份:
    2023
  • 资助金额:
    $ 200万
  • 项目类别:
Broad spectrum inhibitors of paramyxovirus envelope proteins
副粘病毒包膜蛋白的广谱抑制剂
  • 批准号:
    10634368
  • 财政年份:
    2023
  • 资助金额:
    $ 200万
  • 项目类别:
An immunodominance-based Pan-Pneumovirus vaccine for protection against RSV and hMPV
一种基于免疫优势的泛肺炎病毒疫苗,用于预防 RSV 和 hMPV
  • 批准号:
    10735979
  • 财政年份:
    2023
  • 资助金额:
    $ 200万
  • 项目类别:
Generation of highly differentiated NK cells to act in synergy with broadly neutralizing antibodies to reduce the SIV reservoir and establish viral control in absence of ART
生成高度分化的 NK 细胞,与广泛中和抗体协同作用,减少 SIV 储存库,并在没有 ART 的情况下建立病毒控制
  • 批准号:
    10883005
  • 财政年份:
    2023
  • 资助金额:
    $ 200万
  • 项目类别:
Preclinical development of a Nipah Virus inhibitor
尼帕病毒抑制剂的临床前开发
  • 批准号:
    10761349
  • 财政年份:
    2023
  • 资助金额:
    $ 200万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了